Search
Immunic Inc
IMUXAdd to Watchlist
14.580USD
-1.220-7.72%
Close 09-01 16:00（ET）
199.96MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-09-01The current earnings forecast score of Immunic Inc is 9.00, ranking 15 out of 377 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 10.00 and a low of 3.00.
Analyst Rating
Based on
12
analysts
Strong Buy
Current Rating
42.182
Target Price
+173.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Immunic Inc
IMUX
12
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Immunic Inc's price target?
Analysts forecast that Immunic Inc's price target is USD 4.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 3.00.
How have Immunic IncIMUX's recent earnings per share performed?
The market expectation was USD -0.80, while Immunic IncIMUX's earnings per share (EPS) for the previous quarter was USD -10.81. EPS for the next quarter is expected at USD -0.98.
What is the analyst rating for Immunic Inc?
Based on the ratings of Immunic Inc's stock from 12 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.